Hemostemix Announces Private Placement Update
Calgary, Alberta--(Newsfile Corp. - December 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it was granted price protection of its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one...
2020-12-29 9:35 AM EST
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed consolidation of the common shares of the Company on the basis of twenty pre-consolidation shares for one post-consolidation share (the "Consolidation") will take effect, subject to final acceptance by the TSX Venture Exchange, on or about December 30, 2020 under new CUSIP number 423694306....
2020-12-23 11:05 PM EST
Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement
Calgary, Alberta--(Newsfile Corp. - December 18, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,272,117.04 (the "Offering"). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share...
2020-12-18 4:01 PM EST
Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020
Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the quarter ending March 31, 2020 and for the comparable period ending March 31, 2019. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the...
2020-07-13 8:25 AM EDT
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019
Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the...
2020-07-10 8:59 PM EDT
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - July 9, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $266,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 26,650,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase...
2020-07-09 7:00 PM EDT
Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science
Calgary, Alberta--(Newsfile Corp. - July 6, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that the United States District Court for the District of Delaware has granted an order for the expedited briefing schedule on Hemostemix's Injunction application seeking the immediate return of all clinical trial data from Accudata Solutions, Inc. ("Accudata"). The Order directs Defendant Accudata to file an Answering Brief in response to...
2020-07-06 5:47 PM EDT
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and...
2020-07-03 9:15 AM EDT
Hemostemix Appeals Alberta Court's Service Ex Juris Decision
Calgary, Alberta--(Newsfile Corp. - June 24, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, further to its June 19, 2020 news release, Hemostemix has filed a fast track appeal in relation to the Alberta Court of Queen's Bench erroneous service ex juris decision rendered on June 18, 2020 in relation to Hemostemix's Replevin application seeking access to and a copy of Hemostemix's own property which is being wrongfully withheld from Hemostemix...
2020-06-24 8:39 PM EDT
Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of units ("Units") for gross proceeds of up to $700,000 (the "Offering"), subject to TSX Venture Exchange (the "Exchange") approval. The Offering may consist of the issuance of an aggregate of 70,000,000 Units at a price of $0.01 per Unit. Each Unit consists of one Common Share in the capital of the Company...
2020-06-19 9:34 AM EDT
Hemostemix Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order
Calgary, Alberta--(Newsfile Corp. - June 16, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces, that it has not met the revised filing date, as provided in Alberta Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (the "Alberta Order") of the Alberta Securities Commission (and similar exemptions provided by the securities commission in British Columbia) of June 15, 2020, for filing of the following continuous...
2020-06-16 1:23 PM EDT
Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property
Calgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that ownership and control of its intellectual property is an uncontested fact, and the Company is in communication with each clinical trial site. The Company has lawfully and properly cancelled certain license rights to Aspire Health Science, LLC ("Aspire"). "Hemostemix's intellectual property is uncontested," said Thomas Smeenk, CEO. "We reserve...
2020-06-08 1:15 PM EDT
Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials. Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK. Previously, Dr. Argent-Katwala was Director,...
2020-06-03 10:09 AM EDT
Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has retained DLA Piper, a global law firm, and filed for an injunction against Aspire Health Science, LLC, for the return of the Company's property. A hearing for the injunction is set for June 18, 2020 at 10:00 MDT before the Court of Queen's Bench, Alberta. Equally, the Company is pleased to announce DLA Piper filed an amended motion to...
2020-06-03 9:44 AM EDT
Hemostemix Announces Annual Special Meeting Results
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces the Company completed its Annual Special Meeting of Shareholders on May 6, 2020. All motions put forward by management were approved by Shareholders, including the consolidation of the common shares on a one (1) new share for each 20 shares issued. The vote results are detailed in the attached table. Vote Details
2020-05-07 9:15 AM EDT
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,291,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 129,150,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase...
2020-05-07 9:10 AM EDT
Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 30, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir. to its Board of Advisors. David Tsubouchi is the first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister. He has served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of...
2020-04-30 9:15 AM EDT
Hemostemix Announces Private Placement and Debt Settlement Update
Calgary, Alberta--(Newsfile Corp. - April 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that, subject to TSX Venture Exchange ("TSXV") approval, its non-brokered private placement will be increased from $450,000 to $1,223,200 of units (the "Units") at $0.01 per Unit (the "Offering"), and the settlement ("Debt Settlement") of trade payables will amount up to $358,514 at $0.01 per common share. Each Unit of the Offering is comprised...
2020-04-29 9:15 AM EDT
Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors
Calgary, Alberta--(Newsfile Corp. - April 21, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Timothy C. Chang to its Board of Advisors. Mr. Chang is currently a Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of approximately US$1 billion. He has also been a consultant to Newport Healthcare Advisors and to SSG Capital Management. Mr. Chang is a renowned private...
2020-04-21 12:20 PM EDT
Hemostemix Announces the Appointments of Loran Swanberg and Christina Wu, CPA, CGA
Calgary, Alberta--(Newsfile Corp. - April 9, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Loran Swanberg to its Board of Directors. Mr. Swanberg is a successful businessman who increased his ownership of the Company from 0.8% in 2019 to 7.8% in 2020. In combination with Mssrs. Lacey, Hershman and Smeenk, the board now owns 21% of the Company's shares. Mr. Swanberg has been part owner and a director of a private...
2020-04-09 9:15 AM EDT